Vaccines that target blood vessels in kidney cancer to improve immune response
Vaccine Targeting of RCC Blood Vessels to Promote TME Normalization and Enhance TIL Recruitment
This study is looking at how vaccines that target certain proteins in kidney cancer can help make the tumor environment healthier and attract more immune cells to fight the cancer, with the goal of improving outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10903943 on NIH RePORTER |
What this research studies
This research investigates how vaccines targeting blood vessel antigens in renal cell carcinoma (RCC) can help normalize the tumor microenvironment and enhance the recruitment of immune cells. By focusing on the immune context and the networking of immune cells within tumors, the study aims to improve patient outcomes through better immune responses. The approach includes vaccination strategies that have shown promise in both animal models and human trials, potentially leading to improved survival rates for patients with RCC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with renal cell carcinoma who may benefit from enhanced immune responses to their tumors.
Not a fit: Patients with non-immunogenic tumors or those who do not have renal cell carcinoma may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies for patients with renal cell carcinoma, improving their chances of survival.
How similar studies have performed: Previous research has shown success with similar vaccine approaches in enhancing immune responses in cancer treatment, indicating a promising avenue for further exploration.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Storkus, Walter J. — University of Pittsburgh at Pittsburgh
- Study coordinator: Storkus, Walter J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.